Triazolopyridazine compounds, use as inhibitors of the kinase LRRK2, and methods for preparation thereof
申请人:Southern Research Institute
公开号:US09187484B2
公开(公告)日:2015-11-17
Provided are novel LRRK2 kinase inhibitors and methods of treating disease states using these inhibitors. Examples of LRRK2 kinase inhibitors are compounds of the formula:
or derivatives thereof. An example is 1-(piperidin-1-yl)-2-((3-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)thio)butan-1-one. Particular uses include treating neurodegenerative diseases, cancer, autoimmune diseases and leprosy.
A 37-year-old woman with systemic lupus erythematosus and acute allograft failure
作者:Monica P. Revelo、Paisit Pauesakon、Mark Weidner、J.Harold Helderman、Robert G. Horn、Agnes B. Fogo
DOI:10.1016/s0272-6386(00)70066-7
日期:2000.6
US9187484B2
申请人:——
公开号:US9187484B2
公开(公告)日:2015-11-17
[EN] TRIAZOLOPYRIDAZINE COMPOUNDS, USE AS INHIBITORS OF THE KINASE LRRK2, AND METHODS FOR PREPARATION THEREOF<br/>[FR] COMPOSÉS DE TRIAZOLOPYRIDAZINE, UTILISATION COMME INHIBITEURS DE LA KINASE LRRK2, ET PROCÉDÉS POUR LEUR PRÉPARATION
申请人:SOUTHERN RES INST
公开号:WO2013166276A1
公开(公告)日:2013-11-07
The present invention provides novel LRRK2 kinase inhibitors and methods of treating disease states using these inhibitors. Certain triazolopyridazine compounds have been discovered according to the present disclosure that inhibit LRRK2, and therefore find utility in the treatment of a number of disorders neurodegenerative diseases such as Parkinson's disease; precancerous conditions and cancer; autoimmune disorders such as Crohn's disease, rheumatoid arthritis and psoriasis; and leprosy.